Physician profile
Thomas Kunelis
NPI 1558314625
$8,015.39
in general payments reported to CMS, 2019-2025
38 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,484 · 2020: $1,189 · 2021: $726 · 2022: $1,499 · 2023: $1,119 · 2024: $1,024 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,280.04 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,175.91 | 2019-2025 | Trelegy Ellipta, Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $836.67 | 2019-2025 | Ofev, Stiolto Respimat |
| Philips North America LLC | $835.62 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $514.11 | 2019-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $322.23 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Genzyme Corporation | $254.80 | 2019-2025 | |
| Insmed, INC. | $239.14 | 2019-2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $236.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $235.84 | 2020-2025 | Glassia |
| Mylan Specialty L.P. | $226.44 | 2019-2024 | Yupelri |
| Pulmonx Corporation | $205.75 | 2019-2025 | Zephyr Delivery Catheter, Chartis Catheter, Zephyr Endobronchial Valve |
| Regeneron Healthcare Solutions, INC. | $193.26 | 2019-2025 | Dupixent |
| Genentech USA, INC. | $175.13 | 2019-2024 | Xolair |
| Electromed, INC. | $162.54 | 2019-2025 | Smartvest |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kunelis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.